Actively Recruiting
Phase 1 Study of TQB3142 Injection to Assess Safety and How It Acts in Patients With Advanced Malignant Tumors
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2026-06-23
66
Participants Needed
5
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and how the body processes a drug called TQB3142 in adults with advanced malignant tumors. This Phase I clinical trial focuses on patients whose tumors have not responded to standard treatments or who lack effective options, aiming to explore important dosage and safety information. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and targets adults aged 18 to 75 years with confirmed advanced tumors and a good health status to participate safely. Participants receive TQB3142 injections every week during 28-day treatment cycles. The drug is a B-cell lymphoma-extra large inhibitor being studied for its effects in this population. The trial does not include a comparison group and involves a single treatment group receiving the investigational drug. Doses and tolerability are assessed to recommend safe dose levels for future studies. During the study, participants will have regular assessments to monitor safety and how their bodies handle the drug, including laboratory tests and evaluations of adverse events. The main outcomes include identifying dose-limiting toxicities, maximum tolerated doses, and recommended doses for Phase II studies, with follow-up lasting up to 24 months. Researchers will also track response rates, peak drug concentration levels, and monitor any serious side effects. Overall participation can last over two years to ensure thorough safety and effectiveness monitoring.
CONDITIONS
Brief Title
To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors
Research Team
T
Tong Yu Lin, Doctor
H
Hong Yan Tong, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here